Androgens are vital building blocks in maintaining and controlling of male secondary characteristics like bone mass, muscle mass, body structure and spermatogenesis. In case of testosterone replacement therapies, regular steroidal androgens cause undesirable side effects on physicochemical and pharmacokinetic properties. Nonsteroidal selective androgen receptor modulators provide promising alternative to steroidal androgens, because of flexibility of structural modification, tissue selectivity and do not cause undesired traditional steroid related side effects. In the medical world, there is ongoing debate on replacement of testosterone hormone in aging men or age related frailty due to the concern that it could affect prostate, cardiovascular system and serum lipids. However, nonsteriodal selective androgen receptive modulators have arrived at the right time with remarkable ability to selectively stimulate bone and muscle mass with lesser effects on prostate. Previously testosterone replacement therapies using anabolic steroids were last resort in case of anemia, breast cancer and endometriosis. Clinical trials of SARMs transformed the therapeutic use of androgens.
Recently concluded research on vitro and vivo animals suggest remarkable therapeutic promise of selective androgen receptive modulators in treating osteoporosis, hormonal male contraception, and muscle wasting .It was found that SARMs clearly distinguished from their steroidal predecessor in lack of side effects. Though the current research on SARMs is in nascent stage however, proof-of-concept studies and early clinical research shows profound effect on treating muscle wasting upon treatment with testosterone. As more research needs to be carried out to study the action of SARMs on target tissue, days are not far when discovery of novel SARMs will help in broader therapeutic application.Continue reading